Evidence map›Paper›PMID 23852569›Full record

ReviewCurrent gastroenterology reports2013

Fecal microbiota transplantation: indications, methods, evidence, and future directions.

Thomas J Borody, Sudarshan Paramsothy, Gaurav Agrawal

3 registry-linked trialsAbstract readReview
In one paragraph

Review in Current gastroenterology reports, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 125 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
125citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02299973 nacompletednot on this mapstarted 2014, after this paper: background citation

Fecal Microbiota Transplantation in Irritable Bowel Syndrome With Bloating: a Double Blind, Placebo Controlled Randomised Clinical Trial

TypeinterventionalSponsorUniversity Hospital, GhentRan2014 to 2017Enrolled64ConditionsIrritable Bowel SyndromeArmsFMT with donor stool, FMT with own stool
NCT03026231 phase1 / phase2withdrawnnot on this mapstarted 2017, after this paper: background citation

A Prospective, Randomized Placebo Controlled Pilot Study to Characterize the Intestinal Microbiome and to Evaluate the Safety and Fecal Microbiome Changes Following Weekly Administration of Lyophilized PRIM-DJ2727 Given Orally in Subjects With Parkinson's Disease

TypeinterventionalSponsorThe University of Texas Health Science Center, HoustonRan2017 to 2018Enrolled0ConditionsParkinson's DiseaseArmsPRIM-DJ2727, Placebo (for PRIM-DJ2727)
NCT07546942 phase1 / phase2enrolling by invitationnot on this mapstarted 2026, after this paper: background citation

Autism Spectral Disorder (ASD) In Adolescent-Adults Treated by Multimodal Protocol: IV Autologous cSVF, Interval IV Autologous MSCs (Cryopreserved), Strick Ketogenic Diet RESET Program, and Fecal Microbiota Transplantation (FMT)

TypeinterventionalSponsorBlack Tie Medical, Inc.Ran2026 to 2030Enrolled50ConditionsAutism Spectrum Disorder, Autism, Autism Spectral DisorderArmsAutologous MSC isolation, concentration, and cryopreservation of adult mesenchymal stem cells, Fecal Biomicrome Transplantation (FMT), Ketogenic RESET Diet Protocol, Trial combines use of cSVF and MSCs (cryopres) with diet modification and FMT (fecal material Transplant in adult ASD patients, FMT (Fecal Material Tranplantation)
3 · Its place in the literature

Who cites it

125 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Article
  5. Article
  6. Article
  7. Review
  8. Article
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Article
  15. Article
  16. Advances in Fecal Microbiota Transplantation for Gut Dysbiosis-Related Diseases.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  17. Review
  18. Review
  19. Article
  20. Review

65 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Thomas J BorodyCentre for Digestive Diseases, Level 1, 229 Great North Road, Five Dock, Sydney, NSW 2046, Australia. thomas.borody@cdd.com.au
Sudarshan Paramsothy
Gaurav Agrawal

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fecal microbiota transplantation (FMT) has attracted great interest in recent years, largely due to the global Clostridium difficile infection (CDI) epidemic and major advances in metagenomic sequencing of the gastrointestinal (GI) microbiota, with growing understanding of its structure and function. FMT is now recommended as the most effective therapy for relapsing CDI and, with further refinement, may even be used in "first-time" CDI. There is interest also in other conditions related to GI dysbiosis--for example, inflammatory bowel disease, irritable bowel syndrome, obesity, and diabetes mellitus--although quality evidence is at present lacking. A few trials are now underway in FMT for ulcerative colitis. Many unanswered questions remain, including FMT methodology--for example, optimal route of administration, what makes a "good donor," safety issues, and long-term effects of FMT.

Indexed as

Biological TherapyEnterocolitis, PseudomembranousEvidence-Based MedicineFecesGastrointestinal TractHumansInflammatory Bowel DiseasesIrritable Bowel SyndromeMicrobiota

Identifiers

PMID23852569
PMCPMC3742951

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.